Rho kinase regulates induction of T-cell immune dysfunction in abdominal sepsis

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2499-2506

  Hasan, Z ^a   Palani, K ^a   Zhang, S ^a   Lepsenyi, M ^a   Hwaiz, R ^a   Rahman, M ^a   Syk, I ^a   Jeppsson, B ^a   Thorlacius, Henrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; RHO KINASE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; PROTEIN FUNCTION; REGULATORY MECHANISM; SEPSIS; SIGNAL TRANSDUCTION;

AMIDES; ANIMALS; APOPTOSIS; BACTERIAL LOAD; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CECUM; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HMGB1 PROTEIN; IMMUNITY, CELLULAR; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; PYRIDINES; RHO-ASSOCIATED KINASES; SEPSIS; SPLEEN;

EID: 84879425079     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00126-13     Document Type: Article

References (43)

1. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. 2007. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35: 1244-1250
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310
3. Karlsson S, Pettila V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E. 2008. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. 34:1046 -1053
4. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda KI, Nakamua M. 2005. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29:169-175
5. Atefi G, Zetoune FS, Herron TJ, Jalife J, Bosmann M, Al-Aref R, Sarma JV, Ward PA. 2011. Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB J. 25:2500 -2508
6. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:2593-2603
7. Gustot T. 2011. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr. Opin. Crit. Care 17:153-159
8. Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. 1996. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 87:4261-4275
9. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681
10. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A. 2003. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med. 31:2068 -2071
11. Kim JM, Oh YK, Lee JH, Im DY, Kim YJ, Youn J, Lee CH, Son H, Lee YS, Park JY, Choi IH. 2005. Induction of proinflammatory mediators requires activation of the TRAF, NIK, IKK and NF-kappa B signal transduction pathway in astrocytes infected with Escherichia coli. Clin. Exp. Immunol. 140:450-460
12. Fan HK, Cook JA. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10:71- 84
13. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. 1999. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5:221-225
14. Narumiya S. 1996. The small GTPase Rho: cellular functions and signal transduction. J. Biochem. 120:215-228
15. Loirand G, Guerin P, Pacaud P. 2006. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98:322-334
16. Slotta JE, Braun OO, Menger MD, Thorlacius H. 2006. Fasudil, a Rho kinase inhibitor, inhibits leukocyte adhesion in inflamed large blood vessels in vivo. Inflamm. Res. 55:364 -367
17. Hasan Z, Palani K, Rahman M, Zhang S, Syk I, Jeppsson B, Thorlacius H. 2012. Rho kinase signaling regulates pulmonary infiltration of neutrophils in abdominal sepsis via attenuation of CXC chemokine formation and Mac-1 expression on neutrophils. Shock 37:282-288
18. Laschke MW, Dold S, Jeppsson B, Schilling MK, Menger MD, Thorlacius H. 2010. Rho kinase inhibitor attenuates cholestasis-induced CXC chemokine formation, leukocyte recruitment, and hepatocellular damage in the liver. J. Surg. Res. 159:666-673
19. Shin HK, Salomone S, Potts EM, Lee SW, Millican E, Noma K, Huang PL, Boas DA, Liao JK, Moskowitz MA, Ayata C. 2007. Rho kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J. Cereb. Blood Flow Metab. 27:998 -1009
20. Santen S, Wang YS, Laschke MW, Menger MD, Jeppsson B, Thorlacius H. 2010. Rho kinase signalling regulates CXC chemokine formation and leukocyte recruitment in colonic ischemia-reperfusion. Int. J. Colorectal Dis. 25:1063-1070
21. Oka M, Fagan KA, Jones PL, McMurtry IF. 2008. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 155:444-454
22. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173
23. King IL, Mohrs M. 2009. IL-4-producing CD4(+) T cells in reactive lymph nodes during helminth infection are T follicular helper cells. J. Exp. Med. 206:1001-1007
24. Yang W, Yamada M, Tamura Y, Chang K, Mao J, Zou L, Feng Y, Kida K, Scherrer-Crosbie M, Chao W, Ichinose F, Yu Fischman Y-MAJ, Tompkins RG, Yao S, Kaneki M. 2011. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J. Pharmacol. Exp. Ther. 339:832- 841
25. Shinozaki S, Inoue Y, Yang W, Fukaya M, Carter EA, Ming-Yu Y, Fischman A, Tompkins R, Kaneki M. 2010. Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem. Biophys. Res. Commun. 391:1459 -1464
26. Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat. Immunol. 4:330 -336
27. Cavassani KA, Carson WF, Moreira AP, Wen H, Schaller MA, Ishii M, Lindell DM, Dou Y, Lukacs NW, Keshamouni VG, Hogaboam CM, Kunkel SL. 2010. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 115:4403- 4411
28. Taylor AL, Llewelyn MJ. 2010. Superantigen-induced proliferation of human CD4(+)CD25(-) T cells is followed by a switch to a functional regulatory phenotype. J. Immunol. 185:6591- 6598
29. Fu Q, Cui N, Yu W, Du C. 2010. Percentages of CD4+T regulatory cells and HLA-DR expressing monocytes in severe intra-abdominal infections. Scand. J. Infect. Dis. 42:475- 478
30. Gaïni S, Pedersen SS, Koldkjaer OG, Pedersen C, Møller HJ. 2007. High mobility group box-1 protein in patients with suspected communityacquired infections and sepsis: a prospective study. Crit. Care 11:R32
31. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL. 2007. Elevated plasma concentration of IL-6 and elevated APACHEII score predict acute kidney injury in patients with severe sepsis. Clin. J. Am. Soc. Nephrol. 2:22-30
32. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. 1992. Cytokine serum level during severe sepsis in human IL-6 as a maker of severity. Ann. Surg. 215:356 -362
33. Wang HC, Bloom O, Zhang MH, Vishnubhakat JM, Ombrellino M, Che JT, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248 -251
34. Wang H, Yang H, Tracey KJ. 2004. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255:320 -331
35. Ong SP, Lee LM, Leong YFI, Ng ML, Chu JJH. 2012. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. PLoS One 7:e41932.doi:10.1371/journal.pone.0041932.
36. Liu Z, Falo LD, Jr, You Z. 2011. Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J. Immunol. 187: 118-125
37. Tateishi Y, Oda S, Nakamura M, Watanabe K, Kuwaki T, Moriguchi T, Hirasawa H. 2007. Depressed heart rate variability is associated with high IL-6 blood level and decline in the blood pressure in septic patients. Shock 28:549 -553
38. Wakefield CH, Barclay GR, Fearon KCH, Goldie AS, Ross JA, Grant IS, Ramsay G, Howie JC, Scottish Sepsis Intervention Group. 1998. Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Br. J. Surg. 85:818-825
39. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The proand anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813:878-888
40. Jones SA, Richards PJ, Scheller J, Rose-John S. 2005. IL-6 transsignaling: the in vivo consequences. J. Interferon Cytokine Res. 25:241-253
41. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374:1-20
42. Bosmann M, Sarma JV, Atefi G, Zetoune FS, Ward PA. 2012. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB J. 26:1640 -1651
43. Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ferrara JL, Ward PA. 2008. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22:2198-2205.